600557.SH
Jiangsu Kanion Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.27
+0.49%Oct 29, 2026, 07:46 UTC
Kangyuan Pharmaceutical reported third-quarter 2026 revenue of CNY 761 million, up 8.55% year over year, and net profit attributable to shareholders of CNY 64.0772 million, up 11.88%.
Source:Oct 22, 2026, 10:42 UTC
China's National Medical Products Administration approved Jiangsu Kanion Pharmaceutical's Shiwianchang Granules to begin clinical trials for ulcerative colitis.
Source:Aug 27, 2026, 08:02 UTC
Kangyuan Pharmaceutical reported its first-half 2026 results: net profit attributable to shareholders of 147 million yuan, up 3.36% year-on-year.
Source: